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ABSTRACT
Introduction: Appropriatelymanagingmental disorders is a growing priority across countries in view of the
impact on morbidity and mortality. This includes patients with bipolar disorders (BD). Management of BD is
a concern as this is a complex disease with often misdiagnosis, which is a major issue in lower and middle-
income countries (LMICs) with typically a limited number of trained personnel and resources. This needs to
be addressed.
Areas covered: Medicines are the cornerstone of managing patients with Bipolar II across countries
including LMICs. The choice of medicines, especially antipsychotics, is important in LMICs with high rates
of diabetes and HIV. However, care is currently compromised in LMICs by issues such as the stigma, cultural
beliefs, a limited number of trained professionals and high patient co-payments.
Expert opinion: Encouragingly, some LMICs have introduced guidelines for patients with BD; however, this
is very variable. Strategies for the future include addressing the lack of national guidelines for patients with
BD, improving resources for mental disorders including personnel, improving medicine availability and
patients’ rights, and monitoring prescribing against agreed guidelines. A number of strategies have been
identified to improve the treatment of patients with Bipolar II in LMICs, and will be followed up.
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1. Introduction
1.1. General
The treatment of mental disorders is an increasing priority world-
wide as these disorders currently account for between 10% and
13% of the global disease burden and they are also a leading
cause of years lived with disability [1–6]. In addition, currently
over 800,000 people die annually globally from suicide, which is
a leading cause of death in people aged between 15 and 34 years
[7]. The global burden of these disorders has risen in recent years,
especially among lower and middle-income countries (LMICs), as
a result of demographic, environmental, unrest and socio-politi-
cal changes [8–10]. For instance, there has been an appreciable
increase in the burden of mental disorders in the Eastern
Mediterranean Region in recent years with increasing levels of
instability as well as stigma associated with mental health [10–
12]. In Ethiopia, mental illness is now the leading non-
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communicable disease (NCD) in terms of its overall burden [13],
and in Lebanon, approximately one-quarter of the population
have had at least one mental disorder with 10.5% of the popula-
tion experiencing more than one disorder at some stage [14]. In
Nigeria, up to 20–30% of population suffer frommental disorders
[15,16], and in South Africa, the lifetime prevalence of anymental
disorder is 30.3% [17]. High rates of mental health disorders are
also seen in Morocco [18]. This burden will continue rising unless
adequately addressed, increasing the urgency to identify and
appropriately manage patients with mental disorders. However,
there are challenges as there is currently limited government
spending on mental disorders in LMICs including Africa [19,20].
For instance among African countries, spending on mental dis-
orders has been less than 1% of total health-related expenditures
in recent years [19]. Currently, only US$0.1 per capita is being
spent on mental health services by governments in the African
region versus an average of US$21.7 among European countries
[20]. Overall, the median expenditure per capita being spent by
governments on patients with mental health disorders in 2016
was only US$0.02 in low-income countries, rising to US$1.05 in
lower middle-income countries and US$2.62 in higher middle-
income countries [20]. This though compares with US$80.24 in
higher-income countries [20]. In view of the lack of spending on
mental health services, it is perhaps not surprising that in low-
income countries there are less than 2 mental health workers per
100,000 population [21], averaging just 0.9 among African coun-
tries [20]. In Zimbabwe as a low-income country, just 12 psychia-
trists treat a population of 14million [22]. In Ghana despite being
a higher-income country than Zimbabwe, there is still
a considerable gap between the number of patients with mental
health disorders and available facilities to treat them [23], with
fewer than 20 psychiatrists throughout Ghana [23,24]. There are
only approximately 200 psychiatrists in Nigeria serving
a population of 170 million, with only 10% of the population
with common but serious mental disorders receiving minimally
adequate treatment [25]. In Tunisia, there are currently only 3.7
mental health nurses per 100,000 of the population and 2.9
psychosocial care providers [26]; however, there are ongoing
initiatives to improve mental health provision among
nonspecialists including primary health-care physicians to help
address current deficiencies in care provision [11]. Even in South
Africa, only approximately 1 in 4 patients with mental disorders
receive some form of treatment [27]. Overall, it is estimated that
more than 45% of the world’s population live in countries with
less than one psychiatrist for 100,000 patients [28], and more
than 75% of people live in LMICs where there is limited or no
access to mental health services [3]. A limited number of psy-
chiatric beds per capita among LMICs places further strain on the
appropriate management of patients with mental disorders in
these countries [29,30]. Access to effective interventions includ-
ing medicines is also a concern in a number of LMICs. Patient co-
payments for medicines can also be high with potentially cata-
strophic consequences for families if family members become ill
[31,32]. Drug shortages can also affect treatment approaches
[23,33,34]. In addition, currently only a minority of people
affected by mental disorders in LMICs receive even basic treat-
ment worsened, as mentioned, by a lack of trained professionals
to support these patients [3–5,19,35,36]. As a result, there can be
an over-reliance on pharmacotherapy to treat mental disorders
where these are available [33].
A lack of training of health-care professionals in a number of
LMICs, the stigma associated with mental disorders exacer-
bated by preconceptions and cultural issues as well as a lack
of clear referral systems and support to treat mental disorders,
all negatively impact on care provision alongside concerns with
access to care and appropriate treatment [3,4,12,16,23,37–49].
There is also considerable use of traditional medicines and faith
healers in a number of LMICs which may also have a negative
impact on patient outcomes; however, this may not always be
the case [50–52]. With respect to stigma, in Botswana patients
with mental disorders can often be seen as untrustworthy and
cognitively impaired; consequently, they can be discriminated
against in their working environment [53]. Domestic violence
and issues of stigma are also reported among patients with
mental disorders in Pakistan [54] and in Tunisia, there is also still
a considerable social stigma associated with severe mental ill-
ness; however, less for patients with bipolar disorders than
schizophrenia [12]. These barriers and threats to appropriate
diagnosis and management of mental disorders need to be
addressed to improve future care in LMICS [8]. Adequately
addressing human rights' issues in patients with mental disor-
ders could also help in the longer term to improve the care of
patients with mental health disorders [7,8], with ongoing activ-
ities among LMICs to address this [20,55–58].
Consequently, multiple issues including available infrastruc-
ture as well as beliefs are currently appreciable barriers to the
majority of patients with mental disorders receiving adequate
care in LMICs, enhancing the chronicity of their poor mental
health as well as increasing their suffering and costs [2].
Progress is now being made to address a number of these issues
through the WHO mGAP project [23,59,60]. This builds on the
2009 WHO AIMS (World Health Organization Assessment
Instrument for Mental Health Systems) report for LMICs [35] to
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● There are challenges to appropriately manage patients with mental
disorders in lower and middle-income countries (LMICs) due to
limited government spending and a limited number of trained per-
sonnel compared with high-income countries.
● The prevalence of bipolar disease (BD) has increased appreciably in
recent years and is now one of the most disabling diseases
worldwide.
● The management of BD disease is challenging as it can be difficult to
differentiate between the different BD states and between unipolar
depresssion and Bipolar II (BP-II), and there can be appreciable delays
in diagnosis especially in LMICs.
● The management of BP-II includes both pharmacological (lithium,
anticonvulsants, antipsychotics, and antidepressants) and non-phar-
macological approaches; however, there is currently variable avail-
ability of standard treatment guidelines in LMICs to guide patient
care and the prescribing of lithium will depend on available monitor-
ing facilities.
● The choice of antipsychotic is particularly important in sub-Saharan
Africa with high rates of overweight, obesity and Type 2 diabetes,
with care also needed in patients with HIV and BD as some treat-
ments for HIV can increase mental disorders.
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improve access to and the appropriate use of medicines. In
addition, helping to scale up mental health services using
a wide range of different professionals. TheWHO also introduced
the QualityRights initiative in 2013 to improve the care of
patients with mental health disorders [57,58,61,62], with studies
in sites such as Gujarat in India showing that the QualityRights
programme can be effectively implemented in resource-limited
setting to improve the quality of mental health services [61]. We
are also aware of the Partnership for Mental Health Development
in Africa (PaM-D) to bring together diverse stakeholders to help
create an infrastructure to develop mental health research capa-
city and science. This will be achieved through conducting inno-
vative public health-relevant research and seeking to link
research to policy development [63]. In addition, the
PRogramme for Improving Mental health carE (PRIME) project,
which looks at the feasibility of task-sharingmental health care in
LMICs to further improve the care of these patients [36], as well
as partnership networks in low resource settings via nonprofit
organizations to improve the care of patients with mental illness
[64]. However, there is still room for considerable improvement
among LMICs [24,41,63,65].
1.2. Bipolar disorders (BD) including prevalence and
burden of illness
BD is not just one disorder but several, with the age at onset
typically being late adolescence into young adulthood [66–71].
BP-I (Bipolar I) is characterized by episodes of mania. According
to DSM-5, BP-I represents a classic manic depressive disorder
although neither a depressive episode nor psychosis needs to
be present for diagnosis [72]. However, there is ongoing con-
troversy whether unipolar mania should be a seperate diagnosis
from BD-I [73]. BP-II (Bipolar II) is characterized by less severe
manic symptoms, classified as hypomania, however combined
with depressive episodes [69,70,74]. Affected people often
experience prolonged episodes of depression followed by peri-
odic hypomanic episodes [69,75]. However, there is an ongoing
debate about the definition of hypomania [70] and concerns
whether different rating scales for diagnosing (hypo)mania are
interchangeable [76]. In practice, it can be difficult to differentiate
between different BD disorders and other similar conditions,
exacerbated by the presence of mixed states of BD, including
depressive symptoms coexisting with manic symptoms
[70,74,77–81]. BD patients are typically sensitive to depressive
symptoms but may not recognize their hypomanic or manic
symptoms [69].
The prevalence of BD has increased appreciably in recent
years, with a 49.1% increase between 1990 and 2013 [81–83].
However, this may well be due to a greater diagnosis of
Bipolar Spectrum Disorders rather than appreciably increased
prevalence rates. Having said this, increasing urbanization
seen in recent years also appears to increase the prevalence
of psychiatric disorders including BD [84–87]. This is a concern
with a positive relationship seen between increasing urbaniza-
tion and increasing number of suicides [88]. Prevalence rates
for BD vary across countries with an estimated prevalence of
more than 1% of the world’s population [69,89,90] up to 5%
[69,83,91–96]. In their recent review, Clemente et al. (2015)
estimated that the pooled 1-year prevalence of BP-I was 0.71%
(95%CI 0.56–0.86) principally among higher-income countries
and 0.50% (95%CI 0.35–0.64) for BP-II [83]. Among LMICs in
the study by Merikangas et al. (2011), India had the lowest
prevalence of BP-I (0.1%0 and BP-II (0.1%) [95]. There were also
low rates in Lebanon (BP-I 0.4%, BP-II 0.5%) and Romania (BP-I
0.1%, BP-II 0.3%), but higher rates seen in Brazil (BP-I 0.9%, BP-
II 0.2%), Colombia (BP-I 0.7%, BP-II 0.4%) and Mexico (BP-I
0.7%, BP-II 0.1) [95]. Among LMICs in Africa, in Ethiopia and
Nigeria community surveys have suggested a lifetime preva-
lence of BD at 0.1% to 1.83% [97], although these could be
underestimates [98]. In South Africa, an estimated 3–4% of the
population have BD [99]. Underestimates for the prevalence of
BD persist in LMICs as this is often misdiagnosed among
patients with recurrent depression, which has resulted in
calls for these patients to be screened more effectively, espe-
cially to try and detect BP-II [100]. In addition, late-onset BD
also appears underestimated arising from for instance mis-
leading presentations and therapeutic difficulties due to
a high prevalence of somatic comorbidities in these patients
as seen in Tunisia and other countries [101].
BD is seen as one of the most disabling conditions worldwide
[96], with a global burden of 9.9 million disability-adjusted life
years (DALYs) in 2013 [82]. BD is a greater burden to health-care
systems than, for instance, cancer, epilepsy, and Alzheimer’s
disease combined [66], with a 40.9% increase in DALYs attribu-
table to BD between 1990 and 2010 [70] and 49.1% between
1990 and 2013 [82]. However, BD does not have the same
emotive issues as seen with patients with cancer or orphan
diseases [102–105]. Consequently, the appropriate management
of patients with BD has not typically received the same level of
attention among policymakers.
The direct medical costs associated with BD can be high
because of the appreciable use of medical services [66,67,106],
often exacerbated by misdiagnosis and frequent psychiatric
comorbidities [107]. However, there are few published studies
on the costs of BD in LMICs although we are aware that there
have been reviews examining the economic burden of care-
giving for persons with severe mental illness in sub-Saharan
Africa [97,108,109]. The cost of medicines will be a key cost
component in LMICs in line with other disease areas [31].
Indirect costs for patients with BD can also be high due to
its impact on patients and their families, their employers and
society as a whole [66,70].
The effective management of BD is critical because BD is
a serious often disabling condition that can be fatal [68]. Extra
care is also needed during occasions such as Ramadan, which
was associated with higher rates of relapses among patients
with BD in Morocco [110]. The risk of suicide is high during the
depressive episodes of BD [71], with approximately 17% of
patients with BP-I and 24% of patients with BP-II or higher are
likely to attempt suicide during the course of their illness
[69,70,111]. This is important given an increasing rate of sui-
cides in LMICs in recent years, with 79% of global suicides now
occurring in LMICs [6,112,113]. Between 15% and 20%
attempts prove fatal [114]. As a result, BD may account for
a quarter of all completed suicides [115]. In addition, patients
with severe mental disorders have two to three times higher
average mortality compared with the general population,
which reduces life expectancy by 10–20 years [9].
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A considerable proportion of BD patients, even in clinical
remission, also live with significant functional impairment as
seen by high DALY rates [82,96,116–118], with often poor
quality of life among patients with BD [92,119].
In view of this, there is an urgent need across countries to
identify and effectively treat patients with BD in order to reduce
morbidity andmortality rates [90]. During the initial stages of BD,
patient’s symptoms can be confusing and challenging to diag-
nose due to heterogeneous clinical presentations [96]. It can be
difficult to distinguish mania from other psychiatric disorders,
including schizophrenia. The psychosis episodes may be acute
and transient, whichmakesmisdiagnosis of BD patients common
[90,97,111]. There are also concerns about confusion of patients
with BP-II with unipolar depression among health-care profes-
sionals, with an estimated 35–45% of BD patients initially mis-
diagnosed with unipolar depression [81,90,96,115]. As a result,
delays of several years can occur between an initial diagnosis of
amental disorder and a diagnosis of BD [96]. BD patients can also
experience intense, rapidly shifting emotional states [120], with
BD patients experiencing a greater number of mood swings than
others impacting on their functioning [121]. Co-morbidity with
other psychiatric disorders is also common making treatment
complex [69].
Consequently, the principal objective of this paper is to
review current treatment recommendations for patients with
BP-II. Subsequently, discuss potential issues and challenges
among LMICs in managing patients with BP-II in view of the
concerns that have been raised. These include issues with limited
available services and trained personnelmaking differential diag-
nosis and appropriate management challenging [90,96,122,123].
Finally, we will discuss possible ways forward to improve the
management of patients with BP-II in LMICs building on the
considerable experiences of the coauthors. As a result, we will
hopefully provide guidance for all key stakeholder groups on
potential ways to improve the future management of patients
with BD in LMICs. We are unaware of any published studies that
have focused exclusively on current challenges in the manage-
ment of BP-II among LMICs, which is of critical importance given
the many challenges that exist in these countries.
2. Methodology
A number of reviews and guidelines have been published in this
area, including burden of illness studies and studies of attitudes
toward antipsychotic treatment [43,66–69,78,82,90,96,97,107,
124–126]. Consequently, we did not undertake a formal systematic
review. We have based this overview and suggested activities on
pertinent publications known to the coauthors as well as their
extensive experiences across countries as there are only a limited
number of publications on BD and its management in LMICs, with
most publications including guidelines coming from high-income
countries. This is a concern given the considerable challenges that
patients with BD face in LMICs with access to appropriate care
includingmedicines. The coauthors have considerable knowledge
of activities in their own countries to try and address current
challenges and we have used this information to contextualize
potential ways forward. This builds on current activities by the
WHO and others. The countries specifically chosen to provide
additional insight into current challenges and potential ways
forward in LMICs reflect a range of continents, incomes, diversities,
and support systems. These are principally lower- and upper-mid-
dle-income countries since the challenges experienced in these
countries will be enhanced in low-income countries. However, this
is not always the case, e.g. Ethiopia, which is a low-income country,
has developed a comprehensive strategy in recent years to
improve the care of patients with mental health disorders in line
with the WHOmGAP initiative [13,127]. We are also aware that for
instance, it is currently easier to monitor lithium levels in patients
with BD in Kenya, which is a lowmiddle-income country compared
with Botswana, which is an upper-middle-income country.
We have used such approaches before to stimulate debate in
priority disease areas to provide future guidance [128–137]. The
2018 World Bank classification has been used to categorize
countries into LMICs or upper-income countries [138] wherever
pertinent.
3. Current management and challenges with
treating patients with BD especially BP-II
We will first discuss current management approaches for
patients with BD including current controversies, which are
typically based on publications involving high-income coun-
tries given the paucity of publications from LMICs, before
specifically discussing the situation in LMICs. Finally, we will
debate current challenges and the ways forward (under Expert
Opinion) to provide future guidance for LMICs seeking to
improve their care of patients with BD.
3.1. Current management approaches for patients with
BD especially BD-II
The management of BD, especially BP-II, includes both pharma-
cological and non-pharmacological interventions in the acute
phases of mania (or hypomania), in depressive episodes, as well
as for long-term therapy to prevent recurrences [69–71,125,139].
Given the difficulties, several screening instruments have been
developed to aid diagnosis; however, concerns have been raised
with their sensitivity, especially in community settings [69,140].
Typically, detailed questioning of patients is needed to enhance
the diagnosis of BD and in particular the different types [67,69].
Pharmacological interventions are seen as the cornerstone
for managing acute mania or for those who suffer a manic
episode while on long-term treatment [70,90,125,139]. Lithium
was the first treatment used for the management of acute
mania [69,96,141,142]. Because of the side-effects and the risk
of mania after acute withdrawal associated with lithium, other
therapies have since been approved and prescribed including
carbamazepine, valproate, and lamotrigine [67,69–71,141,143].
Valproate has largely replaced lithium in a number of coun-
tries due to concerns with adequately monitoring blood levels
[67,70,143] although lithium is still prescribed and included in
clinical practice guidelines where possible as it has greater
anti-suicidal and other effects compared with other mood
stabilizers [90,125,142,143]. Similar treatments are used for
hypomania [69]. Typically, mood stabilizers such as lithium
and valproate can be combined with an antipsychotic such
as quetiapine, aripiprazole, risperidone or olanzapine as
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a more effective treatment of mania, especially for patients
with more severe mania [67,69,71,81,96,144].
The choice of antipsychotic is particularly important in sub-
Saharan Africa. This region has high and growing rates of
obesity and diabetes. For instance in Nigeria, 62% and 49%
of adults are currently overweight or obese, respectively, [145]
and over 50% of the population in South Africa is currently
overweight or obese [146]. In Botswana, 6% of adults currently
have diabetes with prevalence rates rising with increasing
rates of obesity [147], with similar rates seen in Namibia
[148]. Overall, the prevalence of diabetes is growing across
Africa, with an estimated 16 million adults currently having
diabetes [149]. This is likely to grow to 41 million by 2045 with
increasing urbanization and changing lifestyles [150–152].
Consequently, any treatment prescribed to overweight or dia-
betic patients with BD must include lifestyle changes tailored
to the specific population [9]. In addition, prescribers must be
cognizant of the weight gain potential with antipsychotic
medicines such as olanzapine versus for instance risperidone
and quetiapine (moderate weight gain potential) and aripipra-
zole (low weight gain potential) [153]. Co-morbidities are
a particular issue in patients with BD as adherence to therapies
is already a concern [125,139]. This will be a particular issue in
patients with both mental disorders and HIV necessitating
additional psychosocial support [9,53,154,155], with high
rates of HIV seen in sub-Saharan Africa [154]. There are also
concerns that some treatments for HIV may also result in
mental disorders warranting greater care [155] with these
patients again needing to be carefully managed. This is unlike
the situation in high-income countries.
Acute bipolar depressive episodes are usually managed in
ambulatory care unless there is an imminent risk of suicide
[67]. Typically, antipsychotics such as quetiapine are used to
treat bipolar depression.
However, to date, there are only a limited number of US Food
and Drug Administration (FDA) approved antipsychotics for bipo-
lar depression. These include lurasidone, olanzapine (combined
with fluoxetine) and quetiapine [69,71,90,125], although caripra-
zine has recently been approved by the FDA for BD depression
[156]. Generally, lower starting doses and slower titration are
needed when treating depression compared with mania because
patients with depression are more sensitive and less tolerant to
treatment [69]. Given the limited number of approved medicines,
off-label use of olanzapine monotherapy or in combination with
lithium is common [69]. There is currently controversy surrounding
the prescribing of anticonvulsants for depressive episodes as well
as the prescribing of antidepressants during acute bipolar depres-
sion and maintenance [69,71,81,96]. However, others have sug-
gested that lamotrigine can be prescribed as first-line treatment
for bipolar depression [71]. The risks of using antidepressants
include increased mood cycling and possibly rapid cycling
[67,115,157,158]. This is a concern given the perceived overuse
of antidepressants among BD patients in LMICs [96]. However, co-
prescribing an antidepressant with an antimanic medication such
as lithium, valproate, or quetiapine, may reduce the risk of switch-
ing to mania or hypomania [67,125]. In addition, there may be less
cycling with selective serotonin reuptake inhibitors (SSRIs) than
other antidepressants [70]. Electroconvulsive treatment (ECT) has
also been shown to be effective in BP-II patients with resistant
depression [69,90,125].
With typically 50% cases of recurring within 12 months, pre-
ventative strategies are usually prescribed to reduce these follow-
ing acute episodes [69,70,96]. In BP-II patients, though
controversial, this typically includes a mood stabilizer such as
lithium or valproate combined with an antipsychotic such as
quetiapine or possibly an antidepressant [67,69,96]. However,
antidepressants should be avoided in patients with poor out-
comes to such treatments or in patients with recurrent mixed
symptoms [67,157,159]. Generally, patient attitudes toward anti-
psychotics for maintenance are positive, which is encoura-
ging [126].
In addition, ideally, maintenance treatment should be
aligned with the type of BD, which includes addressing pre-
dominantly depressive symptoms in patients with BP-II [69].
For instance, a patient with BP-II may have a better response
to an anticonvulsant such as lamotrigine as well as potentially
olanzapine or quetiapine, and are more likely to be co-pre-
scribed an antidepressant [67,69,125,160]. Approaches to
improve current poor medication adherence rates include
potential electronic monitoring of patients [161]. This is impor-
tant since, in their recent review, Jaracz et al. found in Poland
that 61% of BD patients were prescribed two medicines,
including mood stabilizers, atypical antipsychotics, and lamo-
trigine, with 22% prescribed three or more medicines [162].
The most common combination was a mood stabilizer with an
atypical antipsychotic (48%). Greater polypharmacy was seen
in BP-I versus BP-II patients [162], with polypharmacy known
to affect adherence rates in practice [163–165].
Medication assessment tools are also being developed to
appraise prescribers’ adherence to evidence-based guidelines
for BD, with such approaches likely to improve care across
countries [166]. Adherence to guidelines has been seen as
a better indicator of the quality of prescribing in ambulatory
care compared with current WHO/INRUD metrics, including
the number of medicines prescribed [167].
3.2. Current management of BD across LMICs
As mentioned, there is generally a paucity of papers describing
prevalence rates and management of patients with BD in LMICs.
A recent paper by Samalin et al. reviewing the management
of BD in six LMICs documented a higher prevalence of BD-I
(72.2%) than BD-II (25.7%) [96]. Overall, 67.2% of BD patients
were prescribed antipsychotics at initial diagnosis, with 51.1%
prescribed first-generation antipsychotics and 51.6% second-
generation antipsychotics. There were concerns with the overuse
of antidepressants with 44.4% of patients prescribed an antide-
pressant at initial diagnosis, principally SSRIs (67.2%), with 29.7%
prescribedmood stabilizers at initial diagnosis [96]. This changed
for long-term maintenance with 87.5% receiving mood stabili-
zers, mainly anticonvulsants (84.3%) and antipsychotics (83.4%),
which were mainly second-generation (79.6%) – more in BP-II
than BP-I patients (91.8% vs. 75.9%, respectively). Overall, 36.1%
of patients were prescribed antidepressants, mainly SSRIs, prin-
cipally in BP-II versus BP-I patients (58.1% vs. 27.8%) [96]. The
time from initial diagnosis of a mental health disorder to diag-
nosis of BP-II was a median of 2.2 years [96].
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Table 1 depicts the current management of BD across a wide
range of LMICs with special emphasis on BP-II acknowledging
concerns with the current paucity of data as well as current
controversies [168]. Table 1 emphasizes that the management
of BD is variable across LMICs; however, pharmacotherapy is seen
as the cornerstone of care in all documented countries. In addi-
tion, some LMICs have introduced standard treatment guidelines
for patients with BD whilst others have not.
3.3. Challenges to the appropriate management of
patients with BD-II especially in LMICs
There are several important challenges to the appropriate man-
agement of patients with BD-II in LMICs. These include concerns
with an accurate diagnosis as well as the availability of trained
professionals and appropriate pharmacotherapies. Table 2 and
Box 1 discuss a number of these issues among selected target
LMICs before discussing potential ways forward (Section 5).
There are a number of common challenges to the manage-
ment of patients with BD-II in LMICs building on comments in
the Introduction and Table 2. In addition to concerns with
stigma, common challenges include the use of traditional
medicines and faith healers as well as cultural issues asso-
ciated with the management of patients with mental disorders
[16,40,43,44,46,47,49]. Common challenges and themes can be
divided into infrastructure and financial issues as well as treat-
ment issues (Box 1). These will be explored further along with
other key issues in Expert Opinion (Section 5).
At the very least, LMICs need to ensure the following
medicines need to be made routinely available for patients
with BP-II in line with the 2019 WHO Essential Medicine
List [227]:
● carbamazepine Tablet (scored): 100 mg; 200 mg.
● lithium carbonate – solid oral dosage form: 300 mg.
● valproic acid (sodium valproate) Tablet (enteric-coated):
200 mg; 500 mg (sodium valproate).
Valproic acid (or potentially carbamazepine) is particularly
important where there are lack of facilities to monitor lithium
blood levels. In addition, second-generation anti-psychotics
such as aripiprazole and quetiapine are becoming cheaper to
help address issues of weight gain.
4. Conclusion
There are a range of activities and actions that LMICs might
consider in the future to address existing barriers and chal-
lenges to the management of patients with BP-II. These
include improving access to services and treatment including
medicines, with potentially mobile clinics and improved train-
ing helping [11,228]. Addressing these challenges represents
a unique opportunity to address the broader issue of increas-
ing access to treatments and care for patients with mental
disorders generally. This includes addressing the current lack
of attention to mental disorders, which remains a central bar-
rier to care not only in LMICs but also in several high-income
countries.
The Gulbenkian Mental Health Platform, an initiative of the
Calouste Gulbenkian Foundation, and the WHO Department of
Mental Health and Substance Abuse, identified a number of
simple, evidence-based actions that policy-makers, public health
professionals and prescribers, especially in LMICs, should under-
take to improve access to, and appropriate use of, medicines for
mental disorders including BD. They include: (1) developing an
evidence-based medicine selection process; (2) promoting infor-
mation and education activities for health-care professionals and
users on the selection process; (3) regulating psychotropic med-
icine availability; (4) implementing a reliable health and supply
chain system; (5) ensuring the quality of psychotropic medicines
including generics; (6) developing a community-based system of
mental health care; (7) developing policies on the affordability of
medicines; (8) developing pricing policies and fostering
a sustainable financing system; (9) adopting evidence-based
guidelines; (10) monitoring the use of psychotropic medicines;
and (11) promoting training initiatives for health-care profes-
sionals on the critical appraisal of scientific evidence and appro-
priate use of psychotropic medicines. This is in addition to
adequately addressing human rights' issues in patients with
mental disorders where these currently exist in LMICs including
implementing the QualityRights program building on current
successes [61].
In conclusion, LMICs should be encouraged to address
mental disorders in the context of their overall health needs
and national programs. Appropriate access to psychotropic
medicines offers the chance of transformative improvement
in health along with other measures as well as the opportunity
for re-engagement in society for people with mental illnesses.
By working at all levels of the health system, it may be
possible to offer this essential component of mental health
care to all who can benefit, building on current examples in
LMICs.
5. Expert opinion
Potential strategies to overcome barriers and existing pro-
blems to the management of BP-II in LMICs start with recogni-
tion of the limited resources currently being spent on mental
disorders in a number of these countries compared with cur-
rent spending on infectious diseases and other NCDs. In addi-
tion, recognizing the human rights of patients with mental
disorders and addressing issues with the stigma that patients
with mental health disorders currently experience [8,35,61].
The lack of focus on mental disorders in some LMICs may be
because of an increasing focus on antimicrobial resistance
(AMR) in recent years due to high inappropriate use of anti-
biotics and its associated consequences on morbidity, mortal-
ity, and costs [229–236]. HIV/AIDs and its management have
also been a particular focus, especially in sub-Saharan Africa,
diverting attention away from mental disorders. In addition,
there has also been an increasing focus on other NCDs such as
hypertension and diabetes in recent years [150,237–240],
again diverting attention and resources away from mental
health disorders.
However, we are now seeing LMICs develop or start to
develop national action plans and prescribing guidance to
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Table 1. Current treatment approaches to the management of patients with BD, especially BD-II among LMICs.
Country Current management approaches
Lower middle-income countries
Ghana ● Currently, there is no clear guidance in the STGs for patients with the different types of BD in Ghana, making it difficult for physicians to
appropriately diagnose and treat the different types of BD [169].
● At the same time, the Mental Health Act in 2012 de-emphasizes institutional care in Ghana, encouraging greater decentralization of mental
health care by enhancing the establishment of services and facilities at the PHC level [29].
● In addition, while some of the first-line medicines recommended for BD-II in international guidelines are listed in the current Essential
Medicines List and the National Health Insurance Scheme medicine lists in Ghana, their lack of availability at most PHCs affects their
accessibility. The few available alternatives at community pharmacies can be expensive with high co-payments [33].
● The newer generation psychotropic medicines are gradually being prescribed more for patients with schizophrenia and BD; however, there is
still considerable prescribing of first-generation antipsychotics as they are inexpensive [33].
India ● The Indian psychiatric society has regularly issued CPGs for the management of BD since 2005 in order to improve the care of these
patients [90]
● The most recent update, published in 2017, clearly outlined the various treatment options and behavioral therapies for patients with BD [90],
which included pharmacological and non-pharmacological interventions as well as ECT.
● Pharmacotherapy is the mainstay of treatment of patients with BD in India, with mood stabilizers used most frequently followed by
antidepressants and antipsychotics. Available mood stabilizers include lithium, valproate, carbamazepine, lamotrigine, and topiramate [90].
Unmanageable patients who refuse medications or who have difficulties with adherence to treatment can be prescribed depot preparations
of antipsychotics [90].
● A recent observational study found that lithium was the most frequently prescribed mood stabilizer, followed by sodium valproate and
carbamazepine [170].
● The main goal of managing bipolar depression is to achieve a normal level of functioning and to avoid switching to hypomanic or manic
episode. Typically, lithium and lamotrigine can be used as first-line treatment in patients with bipolar depression, with quetiapine
monotherapy also seen as potentially beneficial. ECT may also be considered if the depression is severe [90].
● In their recent survey among psychiatrists in India, Reddy et al. ascertained that for acute depression, there was a preference for
a combination of an antidepressant and a mood stabilizer, while ECT is the preferred option to manage severe depression [123]. However,
there were concerns with the extent of antidepressants used to treat BP-II, which requires further investigation [123].
Nigeria ● Both BP-I and BP-II are seen in Nigeria, with the age of onset in Nigeria similar to other published studies [171].
● There are concerns regarding access to care, although recommended treatments for BP-II are in line with international guidelines and
encourage patients to seek help from a psychiatrist [172,173].
● The most common medicines prescribed by psychiatrists for patients with BD are typical antipsychotics either alone or in combination with
mood stabilizers [174]. Tricyclic antidepressants were the most prescribed antidepressant in the majority of studies conducted in tertiary
hospitals in patients with depressive symptoms, with lower costs if clinicians follow published STGs [175,176].
● There are organizations in Nigeria that encourage greater awareness and treatment of patients with mental health disorders such as the
Mentally Aware Nigeria Initiative (MANI) [172], with awareness about BD and its consequences likely to grow following the high profile
suicide of the iconic fashion designer Kate Spade [173].
● Issues of polypharmacy and adherence remain as additional critical concerns in the effective management of BD in Nigeria alongside co-
payments [39,139,176,177].
Pakistan ● The treatment of mental disorders is a continuing concern in Pakistan due to a lack of psychiatrists and trained physicians in addition to the
stigma associated with mental disorders [178].
● These issues adversely affect access to appropriate care in Pakistan [54,179], exacerbated by increasing unemployment, disruptions in social
norms and a high percentage of the population living below the poverty level [54,178,180].
● Despite concerns, CPGs are being followed in Pakistan for the management of BD including the prescribing of lithium, anticonvulsants, anti-
depressants, and anti-psychotics [54].
● Culturally adapted psychoeducation (CaPE) has also been found to be useful for the management of BD in Pakistan [181].
Tunisia ● There have been ongoing developments to improve the management of patients with mental health disorders in Tunisia in recent years
following the publication of the Tunisian National Strategy for the Promotion of Mental Health in 2013 and the creation of the Committee
for Mental Health Promotion in 2015 [11,182].
● More recently, there has been greater training of primary health-care physicians on mental health issues under the WHO mGAP project to
address deficits in the provision of specialist services especially with 30–40% of consultations undertaken by primary health-care physicians
relating to mental health care [11,26,183]. This should help with greater identification and management of patients with depression and
symptoms related to psychosis.
● In their recent study involving 1180 patients with BD across 6 LMICs including Tunisia, Samalin et al. (2016) found that mood stabilizers and
antipsychotics were the most common medicines prescribed for patients with BD. BP-I patients received a higher number of antipsychotics
and anxiolytics than those with BP-II (p < 0.001), and there was an increase in the prescribing of antidepressants in those BD patients with
depressive symptoms (p < 0.001). Overall, the authors found there was an appreciable delay in diagnosis among the participating countries
and, as mentioned, an overuse of antidepressants [96].
● There is also still a considerable social stigma associated with schizophrenia and BD in Tunisia, although significantly less for patients with BD
[12]. This should be helped by ongoing initiatives under the WHO QualityRights initiative [56].
● Hopefully, the ongoing educational and other programs supported by the Ministry of Health in Tunisia will help improve the management of
patients with BD in Tunisia in the future, providing exemplars to other countries.
(Continued )
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Table 1. (Continued).
Country Current management approaches
Zambia ● Little appears to have been achieved in Zambia in the management of mental disorders during the past decade due to financial constraints
and few mental health practitioners in the country, especially psychiatrists, despite for instance efforts by the University of Zambia offering
a Master of Medicine in Psychiatry (MMED), which has suffered from low enrollment.
● However, national STGs and EMLs were developed and approved in 2013 including patients with BD [184,185]. The guidelines discuss bipolar
mood disorders including BP-I, however do not differentiate treatment approaches between BP-I, BP-II and those with mixed BD.
● Pharmacotherapy is the recommended mainstay of treatment. According to the STG, modalities for the treatment of mental disorders are
based on the biopsychosocial model and associated symptomatology, with the clinical characteristics outlined to provide prescribing
guidance [185]
● The STG recommends the use of lithium monotherapy for treatment of mild BP-I, carbamazepine for moderate BD, and sodium valproate in
addition to an antipsychotic agent for severe BD associated with psychosis. However, typically in practice sodium valproate is prescribed as
first line in view of the lack of facilities to monitor lithium levels.
● The recommended treatment for major depressive disorders in the STG consists of antidepressants, psychotherapy, and ECT or a combination
of these [185]. Treatment selection should depend on illness severity, associated features such as rapid cycling or psychosis, and where
possible, patient preference [185].
● These medicines are included on the Zambian EML and made available to patients in public health-care facilities [184].
● In practice though, each clinician generally prescribes medicines based on learned experiences either through their practice or from online
resources. This is seen from the findings from a recent study assessing adherence to antipsychotic treatment guidelines among prescribers in
managing the first episode of psychosis at the largest and only tertiary hospital for in- and out-patients in Zambia. Overall, only 3.2% of
physicians prescribed antipsychotics in line with NICE 2014 guidelines [186], and most prescribers seemed unaware of any guidelines and, if
available, how to use and interpret them.
● There are also concerns with differentiating between the various BD disorders as most clinicians will use DSM 5 or ICD-10 as a guide.
● As a result, typically BP-II is often misdiagnosed with antidepressants such as amitryptyline prescribed in the majority of cases and later
discontinued when patients present with rapid cycling.
Upper-middle-income countries
Botswana ● In Botswana, mood stabilizer anticonvulsants available for the management of BD include sodium valproate, carbamazepine, and
lamotrigine, with sodium valproate the most widely prescribed mood stabilizer for BD.
● Second-generation antipsychotics available in the public system without co-payment include risperidone, olanzapine, and quetiapine.
However, according to current guidance, these medications can only be initiated by a psychiatrist [187].
● Lithium is also available in Botswana to treat BD. However, most patients are rarely started on lithium due to difficulties in laboratory
monitoring. Most hospital laboratories, even referral hospital laboratories, do not perform lithium assays.
● Consequently, most patients who present with BD in Botswana PHCs (typically the place for initial diagnosis and treatment) will be started
on either sodium valproate (majority) or carbamazepine if initially seen by a psychiatric or general nurse. Lamotrigine is rarely started by
nurses. Psychiatrists have a wider choice of medicines available to them.
● As there is also currently no STG in Botswana for the treatment of referred patients, any medicine initiated will currently depend on the
psychiatrist’s assessment and preferences.
Brazil ● There is a national STG for the treatment and management of BP-I; however, in view of current controversies, there is currently no national
STG for BP-II in Brazil [188]. Consequently, in practice, management of patients with BP-II is similar to BP-I, with specific considerations for
the type of disorder and characteristics of each patient.
● Pharmacotherapy is seen as fundamental for the treatment of BD although psychological approaches are also important [188]. Since the
1970s, Brazil has initiated ‘Psychiatric Reform’, which encourages the de-hospitalization of patients with mental disorders and increases their
treatment in the community with an emphasis on outpatient care, without prejudice to general and psychiatric hospitalization when
necessary [189,190].
● For pharmacotherapy of hypomania in patients with BD-II, it is possible for physicians to prescribe lithium, valproic acid, carbamazepine, and
haloperidol, and for depression lithium, valproic acid and fluoxetine hydrochloride within the Brazilian public health system without any co-
payment [191]
● The choice of treatment will depend on the phase of BD, e.g. acute or maintenance treatment, as well as the history of previous responses
combined with the clinical and personal characteristics of the patients.
● Other treatments such as lamotrigine and atypical antipsychotics can be used for patients with BP-II. These medicines can be prescribed
through the private sector, i.e. via private insurance, otherwise 100% co-payment; alternatively supplied free-of-charge following a successful
judicial review [192]. Currently, just under a quarter of the Brazilian population has private insurance.
Bulgaria ● Current antipsychotic treatments for the management of schizophrenia in Bulgaria have improved outcomes for both patients and
caregivers, with relatively low readmission rates at 1 year following discharge [193]. Such studies help to negate negative public attitudes
that psychiatric treatment is not effective, with implications for improved management of patients with BD.
● Additional studies have shown that the burden of severe mental disorders can be considerable, which policymakers must consider when
planning the care of such patients [194].
● There is a mixed utilization pattern with respect to the use of psychotropic medicines for the treatment of mental disorders in Bulgaria
(Figure 1).
● The appreciable decrease in the utilization of risperidone in recent years (Figure 1) could be explained by supply concerns as well as
increased prescribing of newer antipsychotics such as aripiprazole with less weight gain.
(Continued )
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Table 1. (Continued).
Country Current management approaches
Namibia ● Namibia made provision to improve the management of patients with BD-I and II in the Namibian STG [195]
● Bipolar Mood Disorder is defined as a history of depression with at least one episode of mania, with BP-I defined as mania and depression
and BD-II as hypomania and depression.
● Pharmacotherapy is the mainstay of treatment in the STG, with suggested first-line treatments for patients with mood disorders being
clozapine plus lithium or lithium plus valproate or topiramate.
● For depression, lithium with lamotrigine is recommended with a warning about Stevens-Johnson syndrome and DIC [195]
● Recommended second-line treatments are lithium (preferred) or citalopram, paroxetine or venlafaxine with a warning about rapid cycling
potentially induced by antidepressants [195]
● However, specific diagnoses for this category of patients, especially among patients attending PHCs, appears to be lacking, in view of
inadequate facilities and the necessary expertise to achieve optimal diagnosis and management in mental health [196].
● Consequently, BP-II is likely to be diagnosed as a depressive disorder rather than BD-II, and thus managed inappropriately.
South Africa ● The South African government sought to improve the care of patients with mental health disorders through its strategic plan improving
community residential, day care, and outpatient services. Under this system, trained nonspecialist workers could deliver evidence-based
psychosocial interventions and clinical protocols would be available through Integrated Management Guidelines [197,198].
● The South African Depression and Anxiety group has produced a treatment and referral guide to improve the care of BD in South Africa,
which includes definitions of BP-I and BP-II [199]. This can act as an exemplar to other countries.
● Based on current evidence, antipsychotics such as quetiapine and olanzapine as well as lamotrigine are recommended for the long-term
management of depressive symptoms and to reduce relapses, with lithium potentially considered when symptoms have improved [115].
There is also concern that the prescribing of antidepressants may trigger mania [115]
● Alongside this, the 2018 treatment guidance (STG/EML) has just been launched for PHCs. In this, BD is described as a lifelong episodic illness
with the presenting episodes including mania, hypomania, mixed or depressive symptoms [241]
● The 2018 STG/EML states that BD should be confirmed by a specialist, and may present with any mood state with for example treatment-
resistant depression. BP-I includes a current or previous episode of mania with BP-II including hypomania, although this history is not always
clear. This is an improvement from the 2012 STG/EML where there was no distinguishing between BP-I and II [200]
● Prior to this, the South African Society of Psychiatrists published comprehensive treatment guidelines for patients with psychiatric disorders
in 2013 acknowledging that separation of BD patients into BP-I and BP-II can be a challenge. The recommended treatments for patients with
bipolar depression included [201]:
(a) First-line monotherapy includes: Quetiapine 300–600 mg/day, lamotrigine 200–500 mg/day, olanzapine 5–15 mg/day, lithium
and valproate. Second-line options include the following as adjunctive or combination therapies: Adjunctive risperidone 2–4 mg/
day; lithium and antidepressant combinations; olanzapine and fluoxetine combinations; valproate and lithium and lamotrigine as an
add-on to lithium.
(b) If a conventional antidepressant is prescribed, it should be concurrently administered with an antimanic maintenance agent to
diminish switching and the dose gradually tapered after 2–3 months of sustained recovery. Antidepressants should not be
prescribed in rapid-cycling BD patients. Venlafaxine (13 – 15%) and TCAs (7 – 11%) are associated with a relatively higher risk of
inducing a manic switch than SSRIs (0 – 4%).
(c) ECT should only be considered if the risk to self or others is high, if psychotic features are present, or if there has been a
previous response to ECT.
● PHCs may become involved in the management of stable patients once diagnosed and initially treated by a specialist where there is a good
insight into the condition and support [241]. In case of manic, agitated, or acutely disturbed patients, this includes stopping antidepressants
if prescribed.
NB: BD: Bipolar disorders; BP-I: Bipolar I; BP-II: Bipolar II; CPGs: Clinical practice guidelines; ECT: electroconvulsive therapy; EML: Essential Medicines List; PHCs =
Primary Healthcare Centers; STGs – Standard Treatment Guidelines
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Figure 1. Utilization of psychotropic medicines in Bulgaria in recent years (source: (https://www.nhif.bg/page/218)).
NB: DID = DDDs/1000 inhabitants/day.
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Table 2. Key challenges facing LMICs in the management of patients with BD-II especially lower middle-income countries.
Country Key challenges
Lower-middle-income countries
Ghana Identified challenges include:
● a lack of accurate diagnosis and treatment due to the high number of untrained personnel providing mental health care in PHC facilities.
● poor access to psychotropic medicines due to a weak supply system.
● limited capacity for local production of good quality medicines.
● high costs of newer medicines and a lack of dedicated budgets to support procurement of pertinent medicines.
India ● The treatment of mental disorders remains a much-neglected area in India despite many national, state and district level programs [202].
However, progress is being made with the development of CPGs for patients with BD [90].
● Another major challenge is the lack of insurance to cover patients with mental illnesses, especially important because of currently high co-
payments for medicines [203]. This means that patients with severe mental disorders spend a median of 12% of their per capita income on
direct treatment costs [204]. This may start to change with the government seeking to increase funding for healthcare [205].
● Another major challenge to the appropriate care of patients with BD is insufficient number of trained physicians, especially psychiatrists
[206], worsened by well-trained medical practitioners and other health professionals migrating to developed countries [207].
● Inappropriate referral systems also adversely affect patient outcomes [208].
● The lack of awareness about mental illnesses among family members and the community at large limits the effectiveness of prescribed
therapies. Typically, family members play a major role in deciding treatment options in addition to meeting the financial and social needs of
patients [48]. Educating and motivating patients and their caregivers would greatly improve the quality of decision-making in patients with
BD.
Nigeria ● Challenges regarding the effective treatment of patients with BD in Nigeria include mis-information regarding its causes, inadequate
number of mental health specialists, long distances to travel to regional health-care facilities and a poor referral system. For instance, there
is only one neuro-psychiatric hospital for over four million people in the Niger Delta region of Nigeria [209].
● There are also issues with affordability of the medications for patients with mental health disorders [139,209,210].
● These issues need to be addressed along with generally strengthening health system governance around mental health issues because
these disorders have been a neglected area.
● The revised mental health policy in Nigeria is promising hope for the future [211].
Pakistan ● A major challenge for treatment of mental disorders in Pakistan is the scarcity of health-care professionals.
● There is generally only one psychiatrist for every 10,000 people and one psychiatrist for 4 million children in Pakistan suffering from
psychiatric conditions [179], with documented ratios up to one psychiatrist to half a million people [212].
● A second challenge is paucity of information to GPs. Naqvi et al. found that the majority of GPs in Pakistan were unaware of the ICD-10
diagnostic criteria for various mental disorders [42]. Benzodiazepines were the most commonly used medication for all mental disorders
with few GPs familiar with SSRIs or tricyclic antidepressants. In addition, most GPs had not received any recent medical education about
mental disorders, with serious gaps in GPs’ knowledge about the management of mental disorders having serious implications for the
rational use of psychotropic medications [42].
● Other challenges for the appropriate management of patients with BD include a lack of time with physicians and patients’ financial
constraints [54,213].
Tunisia ● Key challenges include:
● Lack of health-care professionals to manage patients with BD, although being eased by greater training of primary health-care physicians
on mental health issues [11,26].
● Time before a full diagnosis of BD as well as an overuse of antidepressants [96].
● Adequately addressing issues of the stigma associated with BD to improve future management aided by the QualityRights initiative
[12,56].
Zambia ● Mental illness, despite constituting an appreciable proportion of the burden of disease in Zambia, taking into account predisposing factors
including HIV/AIDS, poverty and unemployment [214], currently receives inadequate attention with only 0.38% of the national health-care
budget directed toward mental illness in 2008 [215].
● Overall, the challenges for patients with BP-II include a lack of STGs on diagnosis and treatment, a lack of techniques to monitor therapeutic
drug levels where pertinent, erratic supply/unavailability of medicines in mental health hospitals and a limited number of mental health
practitioners to make correct diagnoses and suggest treatment. Currently in Zambia, there are only 15 psychiatrists and one psychiatry
pharmacy specialist.
● There are ongoing initiatives and strategies to strengthen the healthcare system including potentially deploying more psychiatry specialists
into PHC facilities alongside instigating laboratory monitoring facilities to guide the use of lithium.
● The government has also made appreciable strides recently to increase the number of mental health workers through the new specialist
training program (STP) for physicians, an undergraduate degree in mental health, and the recently enacted mental health act which passed
into Law in April 2019.
● Improved patient and physician education can hopefully address current concerns with widespread social stigma and discrimination against
people with mental disorders in Zambia [46].
Upper-middle-income countries
Botswana ● Current challenges include difficulties with obtaining reliable estimates of the prevalence of BD in Botswana, including BP-II, in order to
guide future strategies. Currently, national statistics records only show a broad diagnosis of BD, and even recent studies do not make
a distinction between BP-I and BP-II [216,217].
● In addition, since initial diagnosis and treatment of most patients with mental disorders in Botswana, including those with BP-II, is carried
out by psychiatric or general nurses, and there are currently no national STGs for the management of BP-II, there is a high probability of
missing an accurate diagnosis. Consequently, patients presenting in the depressive phase are likely to be initiated on antidepressant
monotherapy.
● Unpredictable medication availability is another challenge. Whilst BD patients who are referred to the national referral hospital or hospitals
with a psychiatrist may be started on lamotrigine or a second-generation antipsychotic, these medications are typically not available at all
times especially in more remote areas.
● Consequently, treatment choices are dictated by which medicines are available which can cause concern.
(Continued )
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improve the health of their patients with mental disorders in
their country, building on the WHO mhGAP initiative, the
QualityRights initiative as well as the PaM-D initiative in sub-
Saharan Africa (Tables 1 and 2) [59,61–63,241,242]. This will
continue as more knowledge about the burden of mental
disorders is developed and discussed. Such activities are
essential to raise the profile of mental health including those
patients with BP-II as well as discussions about the appropriate
management within countries, building on the success of the
WHO in raising the profile of AMR and NCDs such as hyperten-
sion and diabetes. In addition, counteracting the activities of
pharmaceutical companies and others raising the focus on for
instance cancer, which is reflected by governments in high-
income countries paying very high prices for new cancer
medicines with often limited health gain resulting in reduced
funding for other disease areas [102,104,243,244].
Other activities to address current challenges can be further
divided into infrastructure and/or funding issues as well as
management issues building on Box 1.
5.1. Infrastructure/funding issues
We are already seeing in countries such as Zambia (Table 2)
that resources are now being spent to train more health-care
professionals and deploy them in the community to improve
the availability of trained personnel in ambulatory care. There
have also been considerable activities in countries such as
Ethiopia and Tunisia to improve the care of patients with
mental health disorders (Tables 1 and 2). Consequently, this
should improve diagnosis and subsequent management of
patients with mental disorders including those with BP-II,
and can serve as exemplars to other countries. Hopefully, the
situation will also change in South Africa providing guidance
to others to improve care in the community (Tables 1 and 2).
The lack of training of health-care professionals, especially
in ambulatory care, can be addressed through opportunities
for continual professional development in universities, build-
ing on the experiences in Tunisia and Zambia. However, such
activities need to be attractive for professionals or else avail-
able courses may become redundant through lack of interest
(Table 1). This would not be in the best interest of any key
stakeholder group including patients with BD-II.
There also needs to be urgent discussions in LMICs to seek
ways to retain trained health-care professionals rather than
having them leave for higher-income countries to boost their
wages once trained. Increases in the number of psychiatric
beds as well as provision of community facilities devoted to
mental health are also needed. These can be part of ongoing
national action plans surrounding mental health.
5.2. Management issues
Management issues can be divided into educational issues, includ-
ing local guideline development, as well as addressing medicine
availability and co-payment issues alongside improving the infra-
structure for identifying and treating patients with BP-II.
One of the first activities within countries is to produce
nationally agreed guidelines to improve the management of
patients with BP-II including differential diagnosis. This is
important especially with most guidance and practices in the
management of BD based on the USA. This can build on
existing activities within countries such as India, Namibia,
Nigeria and South Africa (Tables 1 and 2) as well as guidance
from the WHO and others. Once developed, the guidance and
the philosophy behind it can be included in the educational
curriculums of physicians, nurses, and pharmacists as well as
form part of any continual professional development program.
Developing national context-specific STGs is also seen as
important to improve the management of patients with BD,
Table 2. (Continued).
Country Key challenges
Brazil ● There are challenges in successfully diagnosing BP-II in Brazil in view of the difficulties in differentiation from unipolar depression with
a higher prevalence of depressive than hypomanic symptoms in BP-II [218].
● There are currently no STGs for the treatment and management of BD-II in Brazil, which can adversely impact on care delivery and available
medicines in the public health-care system.
● It is essential to expand expertise and availability of mental health services in ambulatory care in Brazil for the effective care of patients with
BP-II and other mental disorders in the future. Such integration will improve diagnosis, enhance adherence to treatments, reduce
emergency consultations, and extend follow-up care to patients with severe mental disorders such as BP-II [219].
Namibia ● Considerable challenges still remain with accurate diagnosis of patients with BD-II among PHCs and more widely in Namibia.
● This needs to be addressed through educational and other activities to improve the care of these patients.
South Africa ● There are concerns with the lack of health-care professionals managing patients with mental disorders in the public sector in South Africa,
which represents the largest proportion of patients in South Africa (approximately 84%) [220,221,252].
● Currently, the majority of psychiatrists in South Africa work in the private sector (approximately 60%) causing problems in the public sector
[222]. The situation is even more challenging among public primary health-care centers in rural settings where currently there are only 0.03
psychiatrists per 100 000 population [223].
● As a result, the vision of the South African Government has not been met (Table 1) – not helped by the lack of investment in community-
based psychiatric and psychosocial rehabilitative services in recent years to support de-institutionalization of services. However, this may
change with greater integration of mental health services in primary care and greater task-sharing [36,220,224,225]. The lack of investment
was highlighted by the number of deaths of mentally ill patients in Gauteng Province following the instigation of the National Mental
Health Policy Framework [226].
● There continue to be concerns with lack of transport to accessing care as well as issues such as stigmatization and traditional cultural beliefs
that need to be addressed alongside issues of available trained staff and facilities to improve care for BD patients [221].
● There are also continued concerns with the availability of essential medicines for patients with BD in the public system including olanzapine,
lithium, and citalopram. Improved supply chain management will help here [252].
NB: BD = bipolar disorders; GPs = General Practitioners; PHCs = Primary Health Care; STGs: Standard Treatment Guidelines.
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especially those with BP-II, within countries given current
controversies surrounding the use of antidepressants in
these patients and potential confusion of BP-II with unipolar
depression. National guidelines can be based on international,
regional or other national guidelines from LMICs and subse-
quently adapted to the local situation. It is critical that key
government as well as physician and pharmacist stakeholders
within a country are involved in their development and/or
refinement to enhance adherence to any guidelines produced.
The local context is particularly important in LMICs with their
often high prevalence rates of HIV as well as cardiovascular
diseases including diabetes compared with developed coun-
tries where international guidelines are typically produced. We
have seen there is greater adherence to guidelines in ambu-
latory care if health-care professionals know and trust those
developing the guidelines [245–247]. As mentioned, consid-
eration of local multiple co-morbidities is important in LMICs
when developing and recommending treatment approaches
as well as in addressing key issues surrounding adherence.
Concerns with adherence to prescribed medicines are also
a growing issue when managing patients with BD, including
BP-II in LMICs. Educational and other strategies are needed to
improve rates. Such activities can build on ongoing research
among LMICs, including sub-Saharan African countries, on
ways to improve adherence to medicines in patients with
other NCDs [240,248–251].
Once national STGs have been produced, prescribing in
both ambulatory care and among hospitalized patients should
be monitored to improve subsequent care. This recommenda-
tion is based on the findings in India and Zambia following
their audits versus Pakistan (Table 1).
The unpredictable availability of medicines to treat patients
with BP-II can be improved through improved supply chain
management as seen by recent initiatives in South Africa
[252]. Issues of high co-payments where these exist can poten-
tially be addressed by encouraging greater use of generic
medicines where available, although there can be issues of
quality, as well as seeking access schemes or donors where
possible building on the experiences in Kenya [240,253–256].
The long-term goal is universal access to healthcare, building
on recent examples in Southern Africa [252].
Finally, governments and others should seek to introduce
educational campaigns among patients, including those with
BD, to dispel current myths surrounding mental disorders and
its management. These can build on programs instigated in
countries to reduce patient pressures on physicians and phar-
macists to prescribe and dispense antibiotics for essentially
viral and self-limiting infections [257,258].
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Box 1. Common challenges in the management of BD-II among LMICs
(a) Infrastructure and funding issues
● A lack of priority in countries for managing patients with mental disorders versus infectious diseases and other non-communicable diseases (NCDs). This is
reflected by concerns with current infrastructures as well as resources devoted to mental health disorders versus other NCDs – demonstrated by the lack of
professionals including psychiatrists and psychiatric nurses.
● Lack of training of health-care professionals, e.g. physicians, pharmacists, and nurses, especially in ambulatory care in the management of BD. This is
reflected by concerns with differential diagnosis of BD in practice as well as potentially rapid cycling if BD patients are prescribed anti-depressants in
isolation. In addition, concerns with the high use of benzodiazepines for BD patients in some countries.
(b) Management issues
● Difficulties diagnosing patients with BD and subsequently differentiating between BP-I, BP-II, and mixed disorders.
● Lack of local STGs in LMICs especially for patients with BP-II given current controversies and evidence, as well as a lack of monitoring of prescribing against
current guidelines where these are available.
● Unpredictable availability of medicines to treat patients with BP-II coupled with poor access to psychotropic medicines in addition to high patient co-
payments in a number of LMICs.
● Concerns with insufficient time with patients to fully discuss the condition with them and available treatment options. This is particularly important in
patients with co-morbidities including those with cardiovascular disease and HIV.
● Insufficient resources and time given to increasing adherence to prescribed medicines – which can be a particular issue in BD patients, especially those with
existing co-morbidities.
● Lack of facilities to monitor the use of lithium – including for those patients with BD-II.
● Lack of awareness of mental disorder issues among family members, as well as mis-information regarding the causes of BD and possible treatment
approaches including BD-II.
NB: BD = Bipolar disorders; LMICs = Lower and Middle-income countries; HIV = Human Immunodeficiency Virus; STG = Standard Treatment Guidelines.
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